Lactic Acid Bacteria for Reducing Blue Light-Induced Eye Fatigue
27. juli 2026 oppdatert av: Synbio Tech Inc.
The Application of Lactic Acid Bacteria on Reducing Blue Light-Induced Eye Fatigue in Middle-Aged Adults
With the widespread use of digital devices and prolonged screen exposure, digital eye strain (DES), also known as computer vision syndrome, has become a global public health concern.
Emerging evidence suggests that the gut-eye axis may play an important role in ocular health, as gut microbiota imbalance is associated with systemic inflammation and oxidative stress.
Specific probiotics may help alleviate eye discomfort through modulation of immune responses and enhancement of antioxidant defense mechanisms.
This randomized, double-blind, placebo-controlled study aims to evaluate the efficacy of supplementation with specific probiotics, Bifidobacterium longum BL531 and Lactobacillus reuteri LR1349, in improving digital eye strain symptoms in adults.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Studietype
Intervensjonell
Registrering (Antatt)
150
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Han-Yin Hsu
- Telefonnummer: +886-07-6955680 Ext. 2923
- E-post: hanin@synbiotech.com.tw
Studer Kontakt Backup
- Navn: Chia-Chia Lee
- Telefonnummer: +886-07-6955680 Ext. 2921
- E-post: cclee@synbiotech.com.tw
Studiesteder
-
-
-
Taipei, Taiwan, 106
- National Taiwan Normal University
-
Ta kontakt med:
- Chi-Hao Wu, Professor
- Telefonnummer: +886-02-7749-1427
- E-post: chwu@ntnu.edu.tw
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Men and women aged 20-65 years
- Daily digital screen use >6 hours for at least 1 year
- Mild to severe digital eye strain (CVS-Q score ≥ 6)
- Mild to moderate dry eye symptoms (OSDI ≥ 13)
Exclusion Criteria:
- Amblyopia or strabismus
- Severe eye diseases (e.g., glaucoma , cataract , retinal disorders, severe corneal disease)
- Ocular surgery within the past 12 months
- Chronic systemic diseases (e.g., uncontrolled diabetes, autoimmune disease, severe liver/kidney impairment, cancer)
- Recent use (<1 months) of steroids, antibiotics, immunosuppressants, probiotics, prebiotics, or eye-health supplements
- Pregnant or breastfeeding
- Allergy to probiotics or study product ingredients
- Eating disorders, psychiatric illness, or cognitive impairment affecting compliance
- Any condition judged unsuitable by the investigator
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
Subjects assigned to the placebo group will take one placebo capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.
|
Maltodekstrin
|
|
Eksperimentell: BL531_low dose
Subjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.
|
1×10^10 cfu/day
|
|
Eksperimentell: BL531_high dose
Subjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.
|
2.5×10^10 cfu/day
|
|
Eksperimentell: LR1349_low dose
Subjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.
|
1×10^10 cfu/day
|
|
Eksperimentell: LR1349_high dose
Subjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.
|
2.5×10^10 cfu/day
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Computer Vision Syndrome Questionnaire (CVS-Q)
Tidsramme: Baseline, Week 6, Week 12
|
The CVS-Q is a questionnaire used to assess digital eye strain associated with prolonged digital screen use.
It includes 16 symptoms related to screen exposure.
Total scores are classified as 0-5 (none/minimal), 6-12 (mild), 13-18 (moderate), and ≥19 (severe), with scores ≥6 indicating clinically significant digital eye strain.
|
Baseline, Week 6, Week 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Ocular Surface Disease Index (OSDI)
Tidsramme: Baseline, Week 6, Week 12
|
The Ocular Surface Disease Index (OSDI) is a 12-item questionnaire used to assess the severity of dry eye symptoms and their impact on vision-related function and daily activities.
Total scores range from 0 to 100, with higher scores indicating greater symptom severity.
|
Baseline, Week 6, Week 12
|
|
Basic vision examination
Tidsramme: Baseline and Week 12
|
A comprehensive ophthalmic examination will be performed, including uncorrected distance and near visual acuity, automated refraction, presbyopia assessment, distance and near vision correction, intraocular pressure measurement, and external eye photography for conjunctival hyperemia assessment.
|
Baseline and Week 12
|
|
Pupillary Response Test
Tidsramme: Baseline and Week 12
|
Pupillary response testing will be performed using the Oculus Pentacam HR or an equivalent device to evaluate pupil size and response time under light and dark conditions.
This assessment provides information on the visual system's adaptation to changes in illumination.
|
Baseline and Week 12
|
|
Tear Secretion Assessment
Tidsramme: Baseline and Week 12
|
Tear meniscus height will be measured using the OS1000 Corneal Topographer (SBM sistemi, Italy) or an equivalent device as an indicator of tear secretion.
|
Baseline and Week 12
|
|
Non-Invasive Tear Break-Up Time (NIBUT)
Tidsramme: Baseline and Week 12
|
Non-invasive tear break-up time (NIBUT) will be measured using the OS1000 Corneal Topographer (SBM sistemi, Italy) or an equivalent device to evaluate tear film stability.
A shorter NIBUT is commonly associated with dry eye symptoms and digital eye strain.
|
Baseline and Week 12
|
|
Corneal Tomography and Topography Analysis
Tidsramme: Baseline and Week 12
|
Corneal tomography and topography analysis will be performed using the Oculus Pentacam HR or an equivalent device to evaluate corneal morphology, curvature, thickness, and regularity.
|
Baseline and Week 12
|
|
Accommodative Function Assessment
Tidsramme: Baseline and Week 12
|
Accommodative function will be assessed using the ARK-1s Auto Ref-Keratometer (NIDEK, Japan) or an equivalent device to evaluate the eye's focusing ability and quantify accommodative responses associated with ciliary muscle contraction and relaxation.
|
Baseline and Week 12
|
|
Worth Four Dot Test
Tidsramme: Baseline and Week 12
|
The Worth Four Dot Test will be used to assess binocular vision and fusion ability by evaluating responses to red and green visual targets, including the presence of suppression or diplopia.
|
Baseline and Week 12
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. september 2026
Primær fullføring (Antatt)
31. august 2027
Studiet fullført (Antatt)
31. desember 2027
Datoer for studieregistrering
Først innsendt
27. juli 2026
Først innsendt som oppfylte QC-kriteriene
27. juli 2026
Først lagt ut (Faktiske)
30. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
30. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
27. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- C202605115
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .